2011

Welcome to Volume 10, Issue #9 (18 MAY 2011) of Pharma Marketing News.

How many patients are needed these days to make a drug a billion dollar blockbuster? Less than you think. What are the implications for pharmaceutical marketing?

Welcome to Volume 10, Issue #7 (15 APRIL 2011) of Pharma Marketing News.

Welcome to Volume 10, Issue #5 (10 MARCH 2011) of Pharma Marketing News.

Welcome to Volume 10, Issue #11 (21 JUNE 2011) of Pharma Marketing News.

Many critics of pharma-supported CME believe this support leads to bias. Between 9 May 2011 and 13 September 2011, readers of Pharma Marketing News were asked to answer a few short questions relating to potential bias in industry-supported CME programs and how to limit the need for industry funding of CME. The results are summarized in this article.

Public health officials cannot depend upon their noses to make important decisions. They need actionable real time data. How do they get it?

More and more pharmaceutical company employees are using Twitter. Pharmaguy is looking at pharma employees who have personal Twitter accounts, how they use these accounts, who follows them and whom they follow, and how influential they are. This article is an introduction to the first round of members of this group.

Pharma social networking sites like Facebook and YouTube may lack patient-centered information and can also be sources of misleading information that could potentially do more harm than good.

Sebelius focused on the fact that Teva's study did not contain data for all ages for which this product would be available for use. According to Tina Raine-Bennett, MD, MPH, of the Women's Health Research Institute at Kaiser Permanente Northern California, a principal investigator of the University of California-San Francisco study, it is unreasonable and virtually impossible to study the use of emergency contraception in 11- and 12-year-olds, because only a small fraction of them will have had sex by that age.